Minneapolis, MN (PRWEB) July 26, 2005
Amgen is the worldÂs largest biotechnology company and the eighth largest pharmaceutical company worldwide. Revenues have nearly doubled in the last three years, going from $5.52 billion in 2002 to $10.55 billion in 2004. Yet the majority of revenue is based on twenty-year old technology. Can Amgen continue its amazing revenue growth? Or will it fall behind, lacking the small molecule therapeutics that are the main stay of modern pharmaceuticals?
Arrowhead PublishersÂ new report entitled "Amgen: Profile, Patents and Pipeline" answers these important questions. It provides detailed analysis and information concerning Amgen's business activities. This report also includes a thorough accounting of the companyÂs patents and patent applications.
This report provides an in-depth analysis of AmgenÂs
Â Strategic strengths and weaknesses
Â Current therapeutic products and pipeline of future products
Â Financial analysis, including R&D productivity
Â Current patents and patent applications
Â Alliances, joint ventures and acquisitions
Â Key personnel
Who should buy this report?
Â Biotech and pharmaceutical companies of all sizes interested in understanding AmgenÂs rapid climb to success and its future direction
Â Early stage biotechnology companies interested in understanding Amgen Ventures strategy for investing its $100 million
Â Financial analysts looking for an in-depth technical analysis of AmgenÂs future revenue sources
Key reasons to purchase this report
Â Competitive intelligence
Â Benchmark company performance against the leading biotechnology company
Â Understand what is driving Amgen's growth, and what is holding it back
This 81 page up-to-date report, based on information gathered through the end of the first quarter 2005, contains five tables on AmgenÂs pipeline; a listing of the last three years of granted patents, analyzed by therapeutic area as well as therapeutic form; a breakdown of sales for all key products; both U.S. and International, as well as a list of all patent applications for 2004 through the first quarter of 2005.